Mutation of the PIK3CA Oncogene in Human Cancers

Overview

Journal Br J Cancer

Specialty Oncology

Date 2006 Feb 2

PMID 16449998

Citations 215

Authors

B Karakas

K E Bachman

B H Park

Affiliations

Soon will be listed here.

Abstract

It is now well established that cancer is a genetic disease and that somatic mutations of oncogenes and tumour suppressor genes are the initiators of the carcinogenic process. The phosphatidylinositol 3-kinase signalling pathway has previously been implicated in tumorigenesis, and evidence over the past year suggests a pivotal role for the phosphatidylinositol 3-kinase catalytic subunit, PIK3CA, in human cancers. In this review, we analyse recent reports describing PIK3CA mutations in a variety of human malignancies, and discuss their possible implications for diagnosis and therapy.

Citing Articles

Advances in cancer genomics and precision oncology.

Heo Y, Kim W, Cho Y, Jung J, Kim N, Choi I Genes Genomics. 2025; .

PMID: 39849190 DOI: 10.1007/s13258-024-01614-7.

Durable disease regression with copanlisib treatment in PI3K-mutated metastasizing ameloblastoma: A case report.

Lynch M, Hermida-Viveiros P, Stencel S, Knott H, Al-Maryati R, Obeidin F Rare Tumors. 2025; 17():20363613241309961.

PMID: 39790867 PMC: 11707780. DOI: 10.1177/20363613241309961.

Integrative bioinformatic analysis to identify potential phytochemical candidates for glioblastoma.

Usmani Rana H, Nisar H, Prajapati J, Goswami D, Rawat R, Eyupoglu V Heliyon. 2024; 10(24):e40744.

PMID: 39720087 PMC: 11665539. DOI: 10.1016/j.heliyon.2024.e40744.

Galangin promotes apoptosis by upregulating the pro-apoptotic gene BAX in triple-negative breast cancer.

Sinnarkar S, Suryawanshi P, Dilip A, Bhawalkar J, Ladke V J Egypt Natl Canc Inst. 2024; 36(1):41.

PMID: 39702881 DOI: 10.1186/s43046-024-00246-y.

Ancestral Differences in Anticancer Treatment Efficacy and Their Underlying Genomic and Molecular Alterations.

Luo M, Yang J, Schaffer A, Chen C, Liu Y, Chen Y Cancer Discov. 2024; 15(3):511-529.

PMID: 39601595 PMC: 11875934. DOI: 10.1158/2159-8290.CD-24-0827.

References

Pedrero J, Carracedo D, Pinto C, Zapatero A, Rodrigo J, Suarez Nieto C . Frequent genetic and biochemical alterations of the PI 3-K/AKT/PTEN pathway in head and neck squamous cell carcinoma. Int J Cancer. 2004; 114(2):242-8. DOI: 10.1002/ijc.20711. View

Kang S, Bader A, Vogt P . Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic. Proc Natl Acad Sci U S A. 2005; 102(3):802-7. PMC: 545580. DOI: 10.1073/pnas.0408864102. View

Colleoni M, Rotmensz N, Peruzzotti G, Maisonneuve P, Mazzarol G, Pruneri G . Size of breast cancer metastases in axillary lymph nodes: clinical relevance of minimal lymph node involvement. J Clin Oncol. 2005; 23(7):1379-89. DOI: 10.1200/JCO.2005.07.094. View

Wymann M, Marone R . Phosphoinositide 3-kinase in disease: timing, location, and scaffolding. Curr Opin Cell Biol. 2005; 17(2):141-9. DOI: 10.1016/j.ceb.2005.02.011. View

Saal L, Holm K, Maurer M, Memeo L, Su T, Wang X . PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res. 2005; 65(7):2554-9. DOI: 10.1158/0008-5472-CAN-04-3913. View

Li V, Wong C, Chan T, Chan A, Zhao W, Chu K . Mutations of PIK3CA in gastric adenocarcinoma. BMC Cancer. 2005; 5:29. PMC: 1079799. DOI: 10.1186/1471-2407-5-29. View

Levine D, Bogomolniy F, Yee C, Lash A, Barakat R, Borgen P . Frequent mutation of the PIK3CA gene in ovarian and breast cancers. Clin Cancer Res. 2005; 11(8):2875-8. DOI: 10.1158/1078-0432.CCR-04-2142. View

Kuijt G, Voogd A, van de Poll-Franse L, Scheijmans L, van Beek M, Roumen R . The prognostic significance of axillary lymph-node micrometastases in breast cancer patients. Eur J Surg Oncol. 2005; 31(5):500-5. DOI: 10.1016/j.ejso.2005.01.001. View

Ikenoue T, Kanai F, Hikiba Y, Obata T, Tanaka Y, Imamura J . Functional analysis of PIK3CA gene mutations in human colorectal cancer. Cancer Res. 2005; 65(11):4562-7. DOI: 10.1158/0008-5472.CAN-04-4114. View

10.

Samuels Y, Diaz Jr L, Schmidt-Kittler O, Cummins J, Delong L, Cheong I . Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell. 2005; 7(6):561-73. DOI: 10.1016/j.ccr.2005.05.014. View

11.

Velho S, Oliveira C, Ferreira A, Ferreira A, Suriano G, Schwartz Jr S . The prevalence of PIK3CA mutations in gastric and colon cancer. Eur J Cancer. 2005; 41(11):1649-54. DOI: 10.1016/j.ejca.2005.04.022. View

12.

Wu G, Mambo E, Guo Z, Hu S, Huang X, Gollin S . Uncommon mutation, but common amplifications, of the PIK3CA gene in thyroid tumors. J Clin Endocrinol Metab. 2005; 90(8):4688-93. DOI: 10.1210/jc.2004-2281. View

13.

Parsons D, Wang T, Samuels Y, Bardelli A, Cummins J, Delong L . Colorectal cancer: mutations in a signalling pathway. Nature. 2005; 436(7052):792. DOI: 10.1038/436792a. View

14.

Wu G, Xing M, Mambo E, Huang X, Liu J, Guo Z . Somatic mutation and gain of copy number of PIK3CA in human breast cancer. Breast Cancer Res. 2005; 7(5):R609-16. PMC: 1242128. DOI: 10.1186/bcr1262. View

15.

Diehl F, Li M, Dressman D, He Y, Shen D, Szabo S . Detection and quantification of mutations in the plasma of patients with colorectal tumors. Proc Natl Acad Sci U S A. 2005; 102(45):16368-73. PMC: 1283450. DOI: 10.1073/pnas.0507904102. View

16.

Hennessy B, Smith D, Ram P, Lu Y, Mills G . Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov. 2005; 4(12):988-1004. DOI: 10.1038/nrd1902. View

17.

Ma Y, Wei S, Lin Y, Lung J, Chang T, Whang-Peng J . PIK3CA as an oncogene in cervical cancer. Oncogene. 2000; 19(23):2739-44. DOI: 10.1038/sj.onc.1203597. View

18.

Druker B, Talpaz M, Resta D, Peng B, Buchdunger E, Ford J . Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001; 344(14):1031-7. DOI: 10.1056/NEJM200104053441401. View

19.

Katso R, Okkenhaug K, Ahmadi K, White S, Timms J, Waterfield M . Cellular function of phosphoinositide 3-kinases: implications for development, homeostasis, and cancer. Annu Rev Cell Dev Biol. 2001; 17:615-75. DOI: 10.1146/annurev.cellbio.17.1.615. View

20.

Cantley L . The phosphoinositide 3-kinase pathway. Science. 2002; 296(5573):1655-7. DOI: 10.1126/science.296.5573.1655. View